Background: This study aimed to compare the diagnostic performance of pre-operative evaluation of contrast-enhanced digital mammography (CEDM) and contrastenhanced magnetic resonance imaging (CEMRI) and to evaluate the effect of each modality to the surgical management in women with breast cancer. Methods: This single-institution prospective study was approved by the Institutional Review Board and informed consent was obtained from all patients. From November 2016 to October 2017, 84 patients, who were diagnosed as invasive carcinoma (69/84) and ductal carcinoma in situ (DCIS) (15/84) underwent both CEDM and CEMRI, were enrolled. We correlated the imaging findings and surgical management with pathologic results, and compared the diagnostic performance of both modalities in the detection of index and secondary cancers (multifocality and multicentricity), and occult cancer in contralateral breast. We also evaluated whether CEDM or CEMRI made changes in surgical management of the affected breast attributed to imaging-detected findings. Results: Eighty-four women were included for analysis. CEDM, in comparison to CEMRI, had a significantly higher specificity (66.7% vs 22.2%, P ¼ 0.021), similar sensitivity (94.6% [78/84] Background: Premenopausal women with breast cancer (BC) experience early onset of treatment-induced menopausal syndrome with adjuvant hormone therapy (HT). Isoflavones in the red clover (RC) are biologically active agents providing a source of rapidly available phytoestrogens acting as natural selective estrogen receptor modulators. Aims of the study are: to improve quality of life reducing menopausal symptoms from HT in BC premenopausal women and preventing weight gain and metabolic syndrome with personal lifestyle intervention; to evaluate in vitro safety profile of RC used in combination with adjuvant anti-estrogenic HT. Methods: Eighty-eight premenopausal BC women (DCIS, T1/T2N0-N1M0) receiving adjuvant HT were randomly assigned to have 80 mg/die of RC dry extract (MCE-11) (verum group) or a tablet without active principle (placebo group) for 2 years. Menopausal Rating Score (MRS) questionnaire was given every three months during the first year then biannually. Diet program was personalized with the WCRF/AICR recommendations and Mediterranean diet. Body Max Index (BMI), hip and waist circumference, homeostatic model assessment index (HOMA) and lipid profile (total LDL, HDL cholesterol, triglycerides) were recorded. Pool serum of women from the two groups was run for in vitro evaluation of the safety profile using specific cell lines selected to be representative of hormone-sensitive BC with high expression of estrogen receptor a (MCF7, T47D) and b (BT20). Results: Menopausal symptoms significantly decreased in both groups over time (p < 0.0001). In the verum group BMI, hip and waist circumference were more reduced than in placebo group (P < 0.0001). HDL cholesterol significantly improved over time (p < 0.01). There was no significant difference in endometrial rhyme, while mammary density significantly decreased in both arms (p < 0.0001). In vitro, no significantly differences were observed in cell growth and induction of estrogen regulated/related genes in the cell lines treated with serum from women of the two arms. Background: To evaluate patient-reported outcomes (PROs) and long-term aesthetic outcome (AO) related to radiotherapy (RT) in the breast-conserving therapy setting for breast cancer over time. To explore the agreement between PROs and AO. Methods: Patients treated with breast-conserving therapy at one institute between April 2015 and April 2016 were prospectively included in the cohort. The AO was scored by the patient and by the BCCT.core software. Further PROs were measured with the EORTC QLQ-C30, QLQ-BR23 and the BIBCQ. Patients were evaluated at preset time points over two years. First, we assessed the evolution in time of the PROs and AO. Second, we tested the differences in mean scale scores of the PROs between patients with a favourable and an unfavourable AO. Results: 175 patients were included in the analysis. At baseline unsatisfactory levels were already present for several global, functional, symptom and body image scales. Most unsatisfactory PROs improved significantly up to one year after RT. Fatigue showed a small deterioration at the start of RT, but improved medium thereafter up to one year after RT (mean difference (MD) 7.6, -12.3, respectively and p < 0.001). Cognitive functioning showed a small decrease from at the start of RT with no further significant decrease (MD -4.73, -0.21 and p 0.003, 0.894, respectively). Breast symptoms significantly increased during RT but decreased afterwards up to two years after RT to lower values than at baseline and were then considered satisfactory (MD 15.6, <0.001, 0.005, respectively Breast Oncology, Chiba Cancer Center Hospital, Chiba, Japan Background: SWT is distressing for patients and impairs their quality of life. There are few studies and no consensus in the literature concerning the impact of BC biology on SWT, particularly in each subtype. However, a randomized trial is not possible to study the SWT. We aimed to assess the impact of the SWT and the histological grade (HG) of tumor on DFS. Methods: We retrospectively reviewed the data of Pts with invasive BC who received core needle biopsy (CNB) as diagnosis between January 2007 and June 2017. Pts who required neo-adjuvant chemotherapy were excluded. The primary analysis was a comparison of the DFS between patients who have SWT for 1 month or less (early group) and those who have them for longer than 1 month (late group). Propensity score matching in these groups was calculated based on the menopausal status, cT, cN, ER, PgR and HER2 status. Furthermore, we divided the Pts into 4 groups for the survival analysis as follows: the HH [high grade CNB/high grade surgical specimen (SS)], the LL (Low grade CNB/Low grade SS), LH (Low grade CNB/high grade SS) and the HL group (high grade CNB/low grade SS). Results: We analyzed the data of 1513 patients. Based on the propensity score, the early group and late group had 530 matched patients each. The median age was 62 years, cT1:58%, cT2:36%, cN0:75%, cN1;25%, ER(þ) 82%, PgR(þ) 68%, HER2(þ):12% in both groups. The median diagnosis to curative SWT was 24.2 days in the early group and 46.7 days in the late group. A propensity score-matched model showed the significant difference in the DFS between the early group and the late group (5-year DFS rate, 92.9 vs. 86.6%; p ¼ 0.0014 HR:1.98 1.30 to 3.08). Multivariate analysis revealed that the prognostic factors were significantly associated with cT (HR:2.02 95% CI 1.34 to 3.07), cN (HR:2.68 95% CI 1.78 to 4.04) and SWT (HR: 1.98, 95% CI, 1.30 to 3.08). ER, PgR and HER2 were not independent prognostic factors. The LH group for early group had a shorter DFS than the HL, HH and LL group (p ¼ 0.0013). The HG for late group was not associated with survival. Conclusions: The late group was significant worse in DFS compared with the early group. The histological up-grading of tumor for the early group was associated with worse survival. Legal entity responsible for the study: The authors. Funding: Has not received any funding Disclosure: All authors have declared no conflicts of interest.
Background: Premenopausal women with breast cancer (BC) experience early onset of treatment-induced menopausal syndrome with adjuvant hormone therapy (HT). Isoflavones in the red clover (RC) are biologically active agents providing a source of rapidly available phytoestrogens acting as natural selective estrogen receptor modulators. Aims of the study are: to improve quality of life reducing menopausal symptoms from HT in BC premenopausal women and preventing weight gain and metabolic syndrome with personal lifestyle intervention; to evaluate in vitro safety profile of RC used in combination with adjuvant anti-estrogenic HT. Methods: Eighty-eight premenopausal BC women (DCIS, T1/T2N0-N1M0) receiving adjuvant HT were randomly assigned to have 80 mg/die of RC dry extract (MCE-11) (verum group) or a tablet without active principle (placebo group) for 2 years. Menopausal Rating Score (MRS) questionnaire was given every three months during the first year then biannually. Diet program was personalized with the WCRF/AICR recommendations and Mediterranean diet. Body Max Index (BMI), hip and waist circumference, homeostatic model assessment index (HOMA) and lipid profile (total LDL, HDL cholesterol, triglycerides) were recorded. Pool serum of women from the two groups was run for in vitro evaluation of the safety profile using specific cell lines selected to be representative of hormone-sensitive BC with high expression of estrogen receptor a (MCF7, T47D) and b (BT20). Results: Menopausal symptoms significantly decreased in both groups over time (p < 0.0001). In the verum group BMI, hip and waist circumference were more reduced than in placebo group (P < 0.0001). HDL cholesterol significantly improved over time (p < 0.01). There was no significant difference in endometrial rhyme, while mammary density significantly decreased in both arms (p < 0.0001). In vitro, no significantly differences were observed in cell growth and induction of estrogen regulated/related genes in the cell lines treated with serum from women of the two arms. Background: To evaluate patient-reported outcomes (PROs) and long-term aesthetic outcome (AO) related to radiotherapy (RT) in the breast-conserving therapy setting for breast cancer over time. To explore the agreement between PROs and AO. Methods: Patients treated with breast-conserving therapy at one institute between April 2015 and April 2016 were prospectively included in the cohort. The AO was scored by the patient and by the BCCT.core software. Further PROs were measured with the EORTC QLQ-C30, QLQ-BR23 and the BIBCQ. Patients were evaluated at preset time points over two years. First, we assessed the evolution in time of the PROs and AO. Second, we tested the differences in mean scale scores of the PROs between patients with a favourable and an unfavourable AO. Results: 175 patients were included in the analysis. At baseline unsatisfactory levels were already present for several global, functional, symptom and body image scales. Most unsatisfactory PROs improved significantly up to one year after RT. Fatigue showed a small deterioration at the start of RT, but improved medium thereafter up to one year after RT (mean difference (MD) 7.6, -12.3, respectively and p < 0.001). Cognitive functioning showed a small decrease from at the start of RT with no further significant decrease (MD -4.73, -0.21 and p 0.003, 0.894, respectively). Breast symptoms significantly increased during RT but decreased afterwards up to two years after RT to lower values than at baseline and were then considered satisfactory (MD 15.6, .1 and p < 0.001, <0.001, 0.005, respectively). AO scored by the patient and with the BCCT.core associated well with each other and with the body image measures. There was no association between AO and global cancer-related QOL in the present cohort.
Conclusions: Small quality of life impairments present during RT with good recovery up to one year after RT. Body image is disturbed during RT and improves up to two years after RT. Around one third of patients score their long-term AO as unfavourable and these PROs correlate well with body image. Legal entity responsible for the study: Caroline Weltens. Background: SWT is distressing for patients and impairs their quality of life. There are few studies and no consensus in the literature concerning the impact of BC biology on SWT, particularly in each subtype. However, a randomized trial is not possible to study the SWT. We aimed to assess the impact of the SWT and the histological grade (HG) of tumor on DFS. Methods: We retrospectively reviewed the data of Pts with invasive BC who received core needle biopsy (CNB) as diagnosis between January 2007 and June 2017. Pts who required neo-adjuvant chemotherapy were excluded. The primary analysis was a comparison of the DFS between patients who have SWT for 1 month or less (early group) and those who have them for longer than 1 month (late group). Propensity score matching in these groups was calculated based on the menopausal status, cT, cN, ER, PgR and HER2 status. Furthermore, we divided the Pts into 4 groups for the survival analysis as follows: the HH [high grade CNB/high grade surgical specimen (SS)], the LL (Low grade CNB/Low grade SS), LH (Low grade CNB/high grade SS) and the HL group (high grade CNB/low grade SS). Results: We analyzed the data of 1513 patients. Based on the propensity score, the early group and late group had 530 matched patients each. The median age was 62 years, cT1:58%, cT2:36%, cN0:75%, cN1;25%, ER(þ) 82%, PgR(þ) 68%, HER2(þ):12% in both groups. The median diagnosis to curative SWT was 24.2 days in the early group and 46.7 days in the late group. A propensity score-matched model showed the significant difference in the DFS between the early group and the late group (5-year DFS rate, 92.9 vs. 86.6%; p ¼ 0.0014 HR:1.98 1.30 to 3.08). Multivariate analysis revealed that the prognostic factors were significantly associated with cT (HR:2.02 95% CI 1.34 to 3.07), cN (HR:2.68 95% CI 1.78 to 4.04) and SWT (HR: 1.98, 95% CI, 1.30 to 3.08). ER, PgR and HER2 were not independent prognostic factors. The LH group for early group had a shorter DFS than the HL, HH and LL group (p ¼ 0.0013). The HG for late group was not associated with survival. Conclusions: The late group was significant worse in DFS compared with the early group. The histological up-grading of tumor for the early group was associated with worse survival. Legal entity responsible for the study: The authors. Background: Fat grafting (FG) has become widely used in breast reconstruction after breast cancer (BC). FG might express protumorigenic factors or alter radiological aspect of the breast, raising some concerns on its oncological safety. The aim of the study was to describe clinical outcome of patients (pts) undergoing FG. Methods: Records of 424 pts who underwent FG between 2010 and 2017 at the Plastic Surgery Dept. of Padova University were reviewed. Pts without invasive BC or not followed at Istituto Oncologico Veneto were excluded, leaving 206 pts for analysis. Cumulative Incidence of relapse was calculated from first FG. Association between clinico-pathological factors and relapse was explored. Results: Patients were mostly post-menopausal (n ¼ 115, 56%) and the majority had HRþ/HER2-BC (n ¼ 134, 65%). Eight pts (4%) were BRCA-mut carriers. Disease stage at diagnosis was: I (42%), II (34%), III (24%). Median interval from surgery to first FG was 23 months (range 0-257). 336 FG interventions were performed (median per patient: 1, range 1-9). At median follow-up of 38.9 months, 35 pts relapsed (10 locoregional, 25 distant relapses). Cumulative Incidence of relapse according to clinico-pathological subgroups is reported in the table. Semestral hazard rates of relapse in the three years after FG were: 0.010, 0.053, 0.034, 0.007, 0.039, and 0.038, respectively. 59 pts (29%) underwent additional breast imaging over standard recommendation (range 1-6 per patient), and 40 (20%) pts underwent breast biopsies (range 1-4, 10 confirmed a local recurrence).
